Nowture

Mario Grande Abascal is Nowture's Founding Partner and CEO. Co-founders Juan Ramón Morales and Vicente Chiva round out the leadership. The firm also draws scientific guidance from Cesar de la Fuente-Nunez, a University of Pennsylvania professor specializing in antimicrobial resistance.

Nowture is an active member of AseBio, Spain's national bioindustry association, and Bioga, the Galician life sciences cluster. These memberships place the firm at the intersection of academic research, startup formation, and regulatory networks in Spanish biotechnology — a sourcing channel that surfaces university spinouts and pre-institutional rounds.

Nowture does not publicly disclose a traditional fund structure or AUM. Its investment activity — including the Libera Bio round — suggests a deal-by-deal model where the firm originates and syndicates transactions, bringing in co-investors from Spain's family-office and public-investment ecosystem.

Yes. Nowture's Libera Bio investment included co-investment from Rosp Corunna, the family office of Sandra Ortega (daughter of Inditex founder Amancio Ortega), and Galicia InnovaTech, a vehicle managed by the regional government of Galicia. This pattern indicates Nowture operates as a convenor of mixed public-private capital.

Nowture's stated strategy spans early-stage seed, startup, expansion, late-stage, growth, and succession — essentially full life-cycle coverage. The firm's disclosed biotech activity has been at early to mid-stage, but the mandate leaves room for later-stage and special-situation investments.

Nowture identifies as a generalist, but its disclosed investments and industry memberships concentrate heavily in biotechnology, life sciences, and digital health. Its most visible deal is in oncology biotech. Membership in two life-sciences trade bodies confirms sector emphasis despite the generalist label.

Nowture has not disclosed its capital base or AUM. The firm's deal structure — raising co-investment per transaction — means capital sources vary by deal. The Libera Bio round drew funds from a prominent Galician family office and a public innovation fund, indicating Nowture functions as an originator rather than a self-contained pool.